Structural Dynamics of P-Rex1 Complexed with Natural Leads Establishes the Protein as an Attractive Target for

Alaa R Hameed1, Sama Fakhri Ali2, Sarah M S Alsallameh3

  • 1Department of Medical Laboratory Techniques, School of Life Sciences, Dijlah University College, Baghdad, Iraq.

PubMed

Insights

Researchers identified natural compounds that inhibit P-Rex1, a protein driving cancer metastasis. These compounds show strong binding affinity, offering potential new cancer therapies by targeting the PIP3-binding pocket. Further validation is needed for these promising leads.

Area of Science:

  • Biochemistry
  • Computational Chemistry
  • Oncology

Background:

  • Phosphatidylinositol 3,4,5-trisphosphate- (PIP3-) dependent Rac exchanger 1 (P-Rex1) is a Rho guanine nucleotide exchange factor.
  • P-Rex1 activation by Gβγ and PIP3 regulates cell invasion and migration, promoting metastasis in various cancers.

Purpose of the Study:

  • To identify selective natural inhibitors of P-Rex1 by targeting its PIP3-binding pocket.
  • To computationally screen natural molecule libraries for potential P-Rex1 inhibitors.

Main Methods:

  • Virtual screening of natural molecule libraries using FAF-Drugs4 for drug-likeness and toxicity.
  • Molecular docking of filtered compounds into the P-Rex1 PIP3-binding pocket using PyRx AutoDock Vina and GOLD.
  • Molecular dynamics simulations, MMGB/PBSA, and WaterSwap binding energy prediction to validate binding affinity and interactions.

Main Results:

  • Two top-ranked compounds demonstrated high binding affinity to the P-Rex1 PIP3-binding pocket, confirmed by docking scores and binding energies (< -12.7 kcal/mol).
  • Molecular dynamics simulations showed stable interactions and strong contact between the compounds and P-Rex1.
  • Analysis revealed significant hydrogen bonding and favorable Van der Waals interactions, with MMGB/PBSA and WaterSwap confirming strong binding affinity.

Conclusions:

  • P-Rex1 is a druggable target for suppressing cancer metastasis.
  • The identified natural compounds exhibit potent binding affinity and serve as potential leads for developing novel anti-cancer therapeutics.
  • Further in vitro and in vivo validation of these compounds is warranted.